HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Currie, G P Articles by Lipworth, B J Search for Related Content PubMed PubMed Citation Articles by Currie, G P Articles by Lipworth, B J

Airway and systemic effects of hydrofluoroalkane fluticasone and beclomethasone in patients with asthma

Asthma & Allergy Research Group, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK

Correspondence to:
Correspondence to:
Professor B J Lipworth, Asthma & Allergy Research Group, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK;
b.j.lipworth{at}dundee.ac.uk

Background: With the transition to hydrofluoroalkane-134a propellants in metered dose inhalers, it is important to consider the efficacy and safety profiles of formulations containing inhaled corticosteroids. We examined the airway and systemic effects of hydrofluoroalkane-134a fluticasone propionate (FLU-HFA) and beclomethasone dipropionate (BEC-HFA) at recommended labelled doses.

Methods: Twenty mild to moderate asthmatics were randomised in crossover fashion to receive 6 weeks of 500 µg/day followed by 1000 µg/day FLU-HFA and BEC-HFA. Measurements were made at baseline after placebo run in and washout, and after each randomised treatment. The primary airway outcome for benefit was the dose of methacholine provoking a fall in forced expiratory volume in 1 second (FEV₁) of 20% or more (methacholine PD₂₀) and for systemic adverse effects was overnight urinary cortisol/creatinine (OUCC).

Results: For mean responses, both doses of BEC-HFA and FLU-HFA produced significant improvements in PD₂₀ compared with baseline. The improvement was not significantly greater with 1000 µg/day FLU-HFA versus BEC-HFA, a 1.69 fold difference (95% CI 0.94 to 3.04). Both doses of BEC-HFA but not FLU-HFA caused significant suppression of OUCC compared with baseline, with significantly (p<0.05) lower values at 1000 µg/day for BEC-HFA versus FLU-HFA (1.97 fold difference (95% CI 1.28 to 3.02)).

Conclusion: There was no difference in the airway and systemic effects in patients with mild to moderate asthma between FLU-HFA and BEC-HFA at a dose of 500 µg/day. At 1000 µg/day there was increased systemic bioactivity with BEC-HFA compared with FLU-HFA, without any gain in airway efficacy.

Keywords: asthma; hydrofluoroalkane-134a; fluticasone; beclomethasone

This article has been cited by other articles:

				G Frezza, J Terra-Filho, J A B Martinez, and E O Vianna Rapid effect of inhaled steroids on nocturnal worsening of asthma Thorax, July 1, 2003; 58(7): 632 - 633. [Abstract] [Full Text] [PDF]